Emerging Therapies in Antiphospholipid Syndrome.

about

Defibrotide in the treatment of hepatic veno-occlusive disease Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications.

P2860

Q28068332-F99BD88E-F664-475C-AC04-4E038131AE7F Q37699576-1EA58580-5FCF-46F9-942C-F4EF1F91E92B

P2860

Emerging Therapies in Antiphospholipid Syndrome.

Item

http://www.wikidata.org/entity/Q38782057

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Emerging Therapies in Antiphospholipid Syndrome.

@en

type

Item

label

Emerging Therapies in Antiphospholipid Syndrome.

@en

prefLabel

Emerging Therapies in Antiphospholipid Syndrome.

@en

P1476

Emerging Therapies in Antiphospholipid Syndrome.

@en

P2093

Danieli Andrade

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.

Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.

A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.

[Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review].

P2888

s11926-016-0566-z

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-016-0566-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maria G Tektonidou

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009401302

http://www.w3.org/2001/XMLSchema#string

P698

26995745

http://www.w3.org/2001/XMLSchema#string

Emerging Therapies in Antiphospholipid Syndrome.

about

P2860

P2860

Emerging Therapies in Antiphospholipid Syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698